Biomind Labs Inc. announced the commencement of a commercial clinical trial on its proprietary drug candidate BMND06, a novel formulation based on the psychedelic molecule mescaline. Mescaline is a naturally occurring psychedelic compound which has received recognition of its possible therapeutic benefits for many decades. Mescaline acts similar to other psychedelic agents by binding to, and activating, the serotonin 5-HT2A receptor with high affinity.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3396 USD | -2.97% | -2.97% | +239.60% |
1st Jan change | Capi. | |
---|---|---|
+239.60% | 25.39M | |
+18.09% | 45.01B | |
+46.34% | 40.96B | |
-8.38% | 38.62B | |
+34.66% | 32.6B | |
-8.34% | 27.49B | |
+16.10% | 27.17B | |
+49.73% | 14.61B | |
+36.71% | 12.95B | |
-6.60% | 11.36B |
- Stock Market
- Equities
- BMND.F Stock
- News Biomind Labs Inc.
- Biomind Labs to Commence Commercial Clinical Trial on Its Proprietary Mescaline Candidate BMND06